Vascular Biogenics | VBLT


Peers Price Chg Day Year Date
Clal Biotechnology 32.00 0.40 1.27% -17.53% Sep/04
Compugen 479.60 -2.50 -0.52% -33.09% Sep/04
Prothena 8.55 0.34 4.14% -57.94% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05

Vascular Biogenics traded at $1.41 this Tuesday April 9th, decreasing $0.08 or 5.37 percent since the previous trading session. Looking back, over the last four weeks, Vascular Biogenics lost 14.55 percent. Over the last 12 months, its price fell by 75.30 percent. Looking ahead, we forecast Vascular Biogenics to be priced at 1.40 by the end of this quarter and at 1.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.